drugset
Drugs / DIANEXIN
last change Jul 2013 re-read 3 minutes ago

DIANEXIN

also known as ASP8597 · Dianexina · Dianexine · Diannexin · Recombinant annexin a5 homodimer
Investigated by
Alavita Pharmaceuticals Inc · Astellas Pharma Inc · CTI Clinical Trial and Consulting Services

Trials 2

today NCT01442337 · Ph 2/3 NCT00615966 · Ph 2
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT00615966 Feb 2008 → Jan 2009 — Alavita Pharmaceuticals Inc Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT01442337 Dec 2011 → Jul 2013 — Astellas Pharma Inc Terminated No outcome recorded Stop: Business

Press releases naming this drug 1 release

DateIssuerRelease
2010-11-01 Astellas Pharma Inc Astellas Pharma Inc.: Enter into Option Agreement with Alavita to Acquire Diannexin Assets astellas.com ↗

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as DIANEXIN ChEMBL registry synonym — accepted as the source's own label CHEMBL2364643 ↗
Known as ASP8597 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01442337 ↗
Known as Dianexina ChEMBL registry synonym — accepted as the source's own label CHEMBL2364643 ↗
Known as Dianexine ChEMBL registry synonym — accepted as the source's own label CHEMBL2364643 ↗
Known as Diannexin ClinicalTrials.gov intervention name — accepted as the source's own label NCT00615966 ↗
Known as Recombinant annexin a5 homodimer ChEMBL registry synonym — accepted as the source's own label CHEMBL2364643 ↗
Modality Protein / enzyme biologic “Diannexin, a recombinant form of the endogenous human Annexin V protein” NCT00615966 ↗
Route Intravenous “single dose, 200 µg/kg IV” NCT00615966 ↗